TYK2 and Opportunistic infection: Indeed, there were no alarming reports of herpes zoster, opportunistic infections, thromboembolic events in TYK2 inhibitors clinical trials, in contrast to those on JAK 1, 2, and 3 inhibitors, both in PsO and in other diseases [49,90].